Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Full data from Edge-Gastric are presented at ESMO.
